Mirum Pharmaceuticals Inc
NASDAQ:MIRM

Watchlist Manager
Mirum Pharmaceuticals Inc Logo
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Watchlist
Price: 94.19 USD 0.99%
Market Cap: 4.8B USD

Operating Margin

-8.8%
Current
Improving
by 53.7%
vs 3-y average of -62.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-8.8%
=
Operating Income
$-41.6m
/
Revenue
$471.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-8.8%
=
Operating Income
$-41.6m
/
Revenue
$471.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
4.7B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 72% of companies in the United States of America
Percentile
28th
Based on 14 112 companies
28th percentile
-8.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Mirum Pharmaceuticals Inc
Glance View

Market Cap
4.8B USD
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, Mirum Pharmaceuticals Inc. has carved a niche for itself by specializing in rare liver diseases, a domain that requires both precision and dedication. Founded with a visionary goal, the company primarily focuses on developing treatments that address serious unmet needs within this sphere. At the heart of its operations is the development of maralixibat, a promising drug targeting progressive familial intrahepatic cholestasis and Alagille syndrome, which are both debilitating liver conditions affecting young patients. By addressing these niche markets, Mirum positions itself uniquely, translating complex science into tangible health outcomes. The company makes its money by navigating the rigorous path of drug development, from clinical trials to receiving regulatory approvals, ultimately transforming these therapies into marketable products. Mirum's business model is interlaced with the high stakes world of pharmaceuticals, where innovation meets exhaustive research and development. Revenue generation is contingent upon both the successful commercialization of its drug pipeline and strategic partnerships, which bolster their market reach and resource agility. By engaging closely with healthcare professionals and leveraging compassionate use and expanded access programs, they not only facilitate early adoption but also fuel the momentum needed for market penetration. Moreover, Mirum's commitment to education and engagement strategies fosters a robust ecosystem that underscores the importance of treating rare diseases. This way, the company not only sells its therapeutics but also creates enduring relationships within the medical community, significantly anchoring its financial and operational standing.

MIRM Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-8.8%
=
Operating Income
$-41.6m
/
Revenue
$471.8m
What is Mirum Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Mirum Pharmaceuticals Inc is -8.8%, which is above its 3-year median of -62.5%.

How has Operating Margin changed over time?

Over the last 3 years, Mirum Pharmaceuticals Inc’s Operating Margin has increased from -66.2% to -8.8%. During this period, it reached a low of -170.3% on Dec 31, 2022 and a high of -8.8% on Oct 30, 2025.

Back to Top